Oxidative stress-induced epigenetic changes associated with malignant transformation of human kidney epithelial cells

Oncotarget

Volumn 8, Issue 7, 2017, Pages 11127-11143

  Mahalingaiah, Prathap Kumar S ^a   Ponnusamy, Logeswari ^a   Singh, Kamaleshwar P ^a  

^a TEXAS TECH UNIVERSITY   (United States)

Author keywords

DNA methylation; Epigenetics; Histone modification; Kidney cancer; Oxidative stress

Indexed keywords

DECITABINE; HISTONE H2AX; HISTONE H3; SERINE; AZACITIDINE; DNA (CYTOSINE 5) METHYLTRANSFERASE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; ENZYME INHIBITOR; HISTONE; HYDROGEN PEROXIDE; OXIDIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CARCINOGENICITY; CONTROLLED STUDY; DNA METHYLATION; DNMT1 GENE; DNMT3A GENE; DRUG CYTOTOXICITY; EPIGENETICS; FEMALE; GENE; GENE EXPRESSION; HAT1 GENE; HDAC1 GENE; HISTONE ACETYLATION; HISTONE MODIFICATION; HMT1 GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; KIDNEY TUBULE CELL; KIDNEY TUBULE EPITHELIUM; MALIGNANT TRANSFORMATION; MBD4 GENE; MOUSE; NONHUMAN; OXIDATIVE STRESS; ACETYLATION; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; CELL TRANSFORMATION; CYTOLOGY; DRUG EFFECTS; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; KIDNEY; KIDNEY TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; XENOGRAFT;

ACETYLATION; ANIMALS; AZACITIDINE; BLOTTING, WESTERN; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; HYDROGEN PEROXIDE; KIDNEY; KIDNEY NEOPLASMS; MICE, NUDE; OXIDANTS; OXIDATIVE STRESS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 85012898753     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12091     Document Type: Article

References (87)

1. la Rosa AH, Acker M, Swain S and Manoharan M. The role of epigenetics in kidney malignancies. Cent European J Urol. 2015; 68:157-164.
2. Gago-Dominguez M, Castelao JE, Yuan JM, Ross RK and Yu MC. Lipid peroxidation: a novel and unifying concept of the etiology of renal cell carcinoma (United States). Cancer Causes Control. 2002; 13:287-293.
3. Greenland S, Gago-Dominguez M and Castelao JE. The value of risk-factor ("black-box") epidemiology. Epidemiology (Cambridge, Mass). 2004; 15:529-535.
4. Cavelier G. Theory of malignant cell transformation by superoxide fate coupled with cytoskeletal electrontransport and electron-transfer. Medical hypotheses. 2000; 54:95-98.
5. Deng X, Gao F and May WS. Bcl2 retards G1/S cell cycle transition by regulating intracellular ROS. Blood. 2003; 102:3179-3185.
6. Felty Q, Singh KP and Roy D. Estrogen-induced G1/S transition of G0-arrested estrogen-dependent breast cancer cells is regulated by mitochondrial oxidant signaling. Oncogene. 2005; 24:4883-4893.
7. Mahalingaiah PK, Ponnusamy L and Singh KP. Chronic oxidative stress leads to malignant transformation along with acquisition of stem cell characteristics, and epithelial to mesenchymal transition in human renal epithelial cells. J Cell Physiol. 2015; 230:1916-1928.
8. Lander HM, Hajjar DP, Hempstead BL, Mirza UA, Chait BT, Campbell S and Quilliam LA. A molecular redox switch on p21(ras). Structural basis for the nitric oxidep21( ras) interaction. J Biol Chem. 1997; 272:4323-4326.
9. Liou GY and Storz P. Reactive oxygen species in cancer. Free Radic Res. 2010; 44:479-496.
10. Lee SR, Yang KS, Kwon J, Lee C, Jeong W and Rhee SG. Reversible inactivation of the tumor suppressor PTEN by H2O2. J Biol Chem. 2002; 277:20336-20342.
11. Li Q and Engelhardt JF. Interleukin-1beta induction of NFkappaB is partially regulated by H2O2-mediated activation of NFkappaB-inducing kinase. J Biol Chem. 2006; 281:1495-1505.
12. Cadenas E. Mitochondrial free radical production and cell signaling. Mol Aspects Med. 2004; 25:17-26.
13. Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, Leake D, Godden EL, Albertson DG, Nieto MA, Werb Z and Bissell MJ. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature. 2005; 436:123-127.
14. Wu WS. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev. 2006; 25:695-705.
15. Guo ZY, Hao XH, Tan FF, Pei X, Shang LM, Jiang XL and Yang F. The elements of human cyclin D1 promoter and regulation involved. Clin Epigenetics. 2011; 2:63-76.
16. Acquati S, Greco A, Licastro D, Bhagat H, Ceric D, Rossini Z, Grieve J, Shaked-Rabi M, Henriquez NV, Brandner S, Stupka E and Marino S. Epigenetic regulation of survivin by Bmi1 is cell type specific during corticogenesis and in gliomas. Stem Cells. 2013; 31:190-202.
17. Soto-Reyes E and Recillas-Targa F. Epigenetic regulation of the human p53 gene promoter by the CTCF transcription factor in transformed cell lines. Oncogene. 2010; 29:2217-2227.
18. Herceg Z. Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors. Mutagenesis. 2007; 22:91-103.
19. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM and Kolodner R. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repairdefective human tumor cell lines. Cancer Res. 1997; 57:808-811.
20. Esteller M, Risques RA, Toyota M, Capella G, Moreno V, Peinado MA, Baylin SB and Herman JG. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res. 2001; 61:4689-4692.
21. Esteller M. Epigenetics in Cancer. New England Journal of Medicine. 2008; 358:1148-1159.
22. Wang XQ, Ng RK, Ming X, Zhang W, Chen L, Chu AC, Pang R, Lo CM, Tsao SW, Liu X, Poon RT and Fan ST. Epigenetic regulation of pluripotent genes mediates stem cell features in human hepatocellular carcinoma and cancer cell lines. PLoS One. 2013; 8:e72435.
23. Choudhuri S, Cui Y and Klaassen CD. Molecular targets of epigenetic regulation and effectors of environmental influences. Toxicol Appl Pharmacol. 2010; 245:378-393.
24. Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clarke N, Brown M, Kishida T, Yao M, Latif F and Maher ER. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene. 2010; 29:2104-2117.
25. Gerashchenko GV, Bogatyrova OO, Rudenko EE, Kondratov AG, Gordiyuk VV, Zgonnyk YM, Vozianov OF, Pavlova TV, Zabarovsky ER, Rynditch AV and Kashuba VI. Genetic and epigenetic changes of NKIRAS1 gene in human renal cell carcinomas. Exp Oncol. 2010; 32:71-75.
26. Ramakrishnan S and Pili R. Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma. Cancer J. 2013; 19:333-340.
27. Shenoy N, Vallumsetla N, Zou Y, Galeas JN, Shrivastava M, Hu C, Susztak K and Verma A. Role of DNA methylation in renal cell carcinoma. J Hematol Oncol. 2015; 8:88.
28. Arai E, Kanai Y, Ushijima S, Fujimoto H, Mukai K and Hirohashi S. Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues. International journal of cancer. 2006; 119:288-296.
29. McRonald FE, Morris MR, Gentle D, Winchester L, Baban D, Ragoussis J, Clarke NW, Brown MD, Kishida T, Yao M, Latif F and Maher ER. CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. Mol Cancer. 2009; 8:31.
30. Baldewijns MM, van Vlodrop IJ, Schouten LJ, Soetekouw PM, de Bruïne AP and van Engeland M. Genetics and epigenetics of renal cell cancer. Biochim Biophys Acta. 2008; 1785:133-155.
31. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR and Linehan WM. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 1994; 91:9700-9704.
32. de Martino M, Klatte T, Haitel A and Marberger M. Serum cell-free DNA in renal cell carcinoma: a diagnostic and prognostic marker. Cancer. 2012; 118:82-90.
33. Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards FM, Kishida T, Yao M, Schraml P, Latif F, et al. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res. 2001; 61:7277-7281.
34. Kawai Y, Sakano S, Suehiro Y, Okada T, Korenaga Y, Hara T, Naito K, Matsuyama H and Hinoda Y. Methylation level of the RASSF1A promoter is an independent prognostic factor for clear-cell renal cell carcinoma. Ann Oncol. 2010; 21:1612-1617.
35. Mosashvilli D, Kahl P, Mertens C, Holzapfel S, Rogenhofer S, Hauser S, Büttner R, Von Ruecker A, Müller SC and Ellinger J. Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma. Cancer Sci. 2010; 101:2664-2669.
36. Ellinger J, Kahl P, Mertens C, Rogenhofer S, Hauser S, Hartmann W, Bastian PJ, Büttner R, Müller SC and von Ruecker A. Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. International journal of cancer. 2010; 127:2360-2366.
37. Ziech D, Franco R, Pappa A and Panayiotidis MI. Reactive oxygen species (ROS)-induced genetic and epigenetic alterations in human carcinogenesis. Mutat Res. 2011; 711:167-173.
38. Klaunig JE, Wang Z, Pu X and Zhou S. Oxidative stress and oxidative damage in chemical carcinogenesis. Toxicol Appl Pharmacol. 2011; 254:86-99.
39. Herman JG and Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. The New England journal of medicine. 2003; 349:2042-2054.
40. Robertson KD. DNA methylation and chromatin-unraveling the tangled web. Oncogene. 2002; 21:5361-5379.
41. Campos AC, Molognoni F, Melo FH, Galdieri LC, Carneiro CR, D'Almeida V, Correa M and Jasiulionis MG. Oxidative stress modulates DNA methylation during melanocyte anchorage blockade associated with malignant transformation. Neoplasia. 2007; 9:1111-1121.
42. Kang KA, Zhang R, Kim GY, Bae SC and Hyun JW. Epigenetic changes induced by oxidative stress in colorectal cancer cells: methylation of tumor suppressor RUNX3. Tumour Biol. 2012; 33:403-412.
43. Nishida N and Kudo M. Oxidative stress and epigenetic instability in human hepatocarcinogenesis. Dig Dis. 2013; 31:447-453.
44. Peng DF, Kanai Y, Sawada M, Ushijima S, Hiraoka N, Kitazawa S and Hirohashi S. DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis. 2006; 27:1160-1168.
45. Nishida N, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Inoue T, Minami Y, Ueshima K, Sakurai T and Kudo M. Reactive oxygen species induce epigenetic instability through the formation of 8-hydroxydeoxyguanosine in human hepatocarcinogenesis. Dig Dis. 2013; 31:459-466.
46. Wu Q and Ni X. ROS-mediated DNA methylation pattern alterations in carcinogenesis. Curr Drug Targets. 2015; 16:13-19.
47. Li M, Wang Y, Song Y, Bu R, Yin B, Fei X, Guo Q and Wu B. Aberrant DNA methyltransferase 1 expression in clear cell renal cell carcinoma development and progression. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu. 2014; 26:371-381.
48. O'Hagan HM, Wang W, Sen S, Destefano Shields C, Lee SS, Zhang YW, Clements EG, Cai Y, Van Neste L, Easwaran H, Casero RA, Sears CL and Baylin SB. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell. 2011; 20:606-619.
49. Laget S, Miotto B, Chin HG, Estève PO, Roberts RJ, Pradhan S and Defossez PA. MBD4 cooperates with DNMT1 to mediate methyl-DNA repression and protects mammalian cells from oxidative stress. Epigenetics. 2014; 9:546-556.
50. Futscher B. (2013). Epigenetic Changes During Cell Transformation. In: Karpf AR, ed. Epigenetic Alterations in Oncogenesis: Springer New York), pp. 179-194.
51. Glozak MA and Seto E. Histone deacetylases and cancer. Oncogene. 2007; 26:5420-5432.
52. Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A, Bernard L, Draetta GF, Alcalay M, Seiser C and Chiocca S. Role for histone deacetylase 1 in human tumor cell proliferation. Molecular and cellular biology. 2007; 27:4784-4795.
53. Minucci S and Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature reviews Cancer. 2006; 6:38-51.
54. Zupkovitz G, Grausenburger R, Brunmeir R, Senese S, Tischler J, Jurkin J, Rembold M, Meunier D, Egger G, Lagger S, Chiocca S, Propst F, Weitzer G, et al. The cyclin-dependent kinase inhibitor p21 is a crucial target for histone deacetylase 1 as a regulator of cellular proliferation. Molecular and cellular biology. 2010; 30:1171-1181.
55. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE and Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate. 2004; 59:177-189.
56. Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M, Raju GC and Hooi SC. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 2005; 12:395-404.
57. Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Staber PB, Zatloukal K and Denk H. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther. 2006; 5:2203-2210.
58. Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D and Blaheta RA. The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J Cell Mol Med. 2009; 13:2376-2385.
59. Lin HY, Chen CS, Lin SP and Weng JR. Targeting histone deacetylase in cancer therapy. Medicinal research reviews. 2006; 26:397-413.
60. Insinga A, Monestiroli S, Ronzoni S, Carbone R, Pearson M, Pruneri G, Viale G, Appella E, Pelicci P and Minucci S. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J. 2004; 23:1144-1154.
61. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E and Yao TP. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. Embo j. 2002; 21:6236-6245.
62. Wang F, Nguyen M, Qin FX and Tong Q. SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell. 2007; 6:505-514.
63. Dobosy JR and Selker EU. Emerging connections between DNA methylation and histone acetylation. Cell Mol Life Sci. 2001; 58:721-727.
64. Hellebrekers DM, Griffioen AW and van Engeland M. Dual targeting of epigenetic therapy in cancer. Biochim Biophys Acta. 2007; 1775:76-91.
65. Ng HH and Bird A. Histone deacetylases: silencers for hire. Trends Biochem Sci. 2000; 25:121-126.
66. Sarkar S, Abujamra AL, Loew JE, Forman LW, Perrine SP and Faller DV. Histone deacetylase inhibitors reverse CpG methylation by regulating DNMT1 through ERK signaling. Anticancer Res. 2011; 31:2723-2732.
67. Kondo Y, Shen L and Issa JP. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Molecular and cellular biology. 2003; 23:206-215.
68. Gupta A, Guerin-Peyrou TG, Sharma GG, Park C, Agarwal M, Ganju RK, Pandita S, Choi K, Sukumar S, Pandita RK, Ludwig T and Pandita TK. The mammalian ortholog of Drosophila MOF that acetylates histone H4 lysine 16 is essential for embryogenesis and oncogenesis. Molecular and cellular biology. 2008; 28:397-409.
69. Sharma GG, So S, Gupta A, Kumar R, Cayrou C, Avvakumov N, Bhadra U, Pandita RK, Porteus MH, Chen DJ, Cote J and Pandita TK. MOF and histone H4 acetylation at lysine 16 are critical for DNA damage response and double-strand break repair. Molecular and cellular biology. 2010; 30:3582-3595.
70. Berthiaume M, Boufaied N, Moisan A and Gaudreau L. High levels of oxidative stress globally inhibit gene transcription and histone acetylation. DNA Cell Biol. 2006; 25:124-134.
71. Mahalingam D, Medina EC, Esquivel JA, Espitia CM, Smith S, Oberheu K, Swords R, Kelly KR, Mita MM, Mita AC, Carew JS, Giles FJ and Nawrocki ST. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res. 2010; 16:141-153.
72. Wang Y, Zhang R, Wu D, Lu Z, Sun W, Cai Y, Wang C and Jin J. Epigenetic change in kidney tumor: downregulation of histone acetyltransferase MYST1 in human renal cell carcinoma. J Exp Clin Cancer Res. 2013; 32:8.
73. Valk-Lingbeek ME, Bruggeman SW and van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell. 2004; 118:409-418.
74. Bloushtain-Qimron N, Yao J, Snyder EL, Shipitsin M, Campbell LL, Mani SA, Hu M, Chen H, Ustyansky V, Antosiewicz JE, Argani P, Halushka MK, Thomson JA, et al. Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A. 2008; 105:14076-14081.
75. Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, Yamochi T, Urano T, Furukawa K, Kwabi-Addo B, Gold DL, Sekido Y, Huang TH, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008; 40:741-750.
76. Rogenhofer S, Kahl P, Mertens C, Hauser S, Hartmann W, Büttner R, Müller SC, von Ruecker A and Ellinger J. Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma. BJU Int. 2012; 109:459-465.
77. Niu Y, DesMarais TL, Tong Z, Yao Y and Costa M. Oxidative stress alters global histone modification and DNA methylation. Free Radic Biol Med. 2015; 82:22-28.
78. Rogakou EP, Boon C, Redon C and Bonner WM. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol. 1999; 146:905-916.
79. Tamburini BA and Tyler JK. Localized histone acetylation and deacetylation triggered by the homologous recombination pathway of double-strand DNA repair. Molecular and cellular biology. 2005; 25:4903-4913.
80. Zhu F, Zykova TA, Peng C, Zhang J, Cho YY, Zheng D, Yao K, Ma WY, Lau AT, Bode AM and Dong Z. Phosphorylation of H2AX at Ser139 and a new phosphorylation site Ser16 by RSK2 decreases H2AX ubiquitination and inhibits cell transformation. Cancer Res. 2011; 71:393-403.
81. Zhang Y, Adachi M, Zou H, Hareyama M, Imai K and Shinomura Y. Histone deacetylase inhibitors enhance phosphorylation of histone H2AX after ionizing radiation. Int J Radiat Oncol Biol Phys. 2006; 65:859-866.
82. Milutinovic S, Zhuang Q, Niveleau A and Szyf M. Epigenomic stress response. Knockdown of DNA methyltransferase 1 triggers an intra-S-phase arrest of DNA replication and induction of stress response genes. J Biol Chem. 2003; 278:14985-14995.
83. Chen T, Hevi S, Gay F, Tsujimoto N, He T, Zhang B, Ueda Y and Li E. Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells. Nat Genet. 2007; 39:391-396.
84. Hwang SL YG. Neuroprotective effects of the citrus flavanones against H2O2-induced cytotoxicity in PC12 cells. J Agric Food Chem 2008; 56:859-864.
85. Alarifi S. Assessemnt of MCF-7 cells as an invitro model system for evaluation of chemical oxidative stressors. African Journal of Biotechnology 2011; 10:3872-3879.
86. Ganie SA HE, Hamid A, Masood A, Zargar MA. Long dose exposure of hydrogen peroxide (H2O2) in albino rats and effect of Podophyllum hexandrum on oxidative stress. Eur Rev Med Pharmacol Sci 2011; 15:906-915.
87. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (San Diego, Calif). 2001; 25:402-408.